Prot #SL03-OHD-105: An Open-Label, Phase 1b Study of SL-172154 (SIRPa-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers

Project: Research project

Project Details

StatusActive
Effective start/end date2/21/232/21/26

Funding

  • Parexel ((OE) Prot #SL03-OHD-105-AMND 1 // (OE) Prot #SL03-OHD-105-AMND 1)
  • Shattuck Labs, Inc. ((OE) Prot #SL03-OHD-105-AMND 1 // (OE) Prot #SL03-OHD-105-AMND 1)